Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection

被引：0

作者：

Barker, Peter E. ^{[1
]}

Murthy, Mahadev ^{[2
]}

机构：

[1] NIST, Bioassay Methods Grp, Biochem Sci Div, Bldg 227-B248,100 Bur Dr, Gaithersburg, MD 20899 USA

[2] NIA, DAB, Bethesda, MD 20892 USA

来源：

BIOMARKER INSIGHTS | 2009年 / 4卷

关键词：

biomarker; aging; cancer; validation; mitochondrial DNA (mtDNA) sequencing; technology; economic impact; healthcare; mitochondriome; mutation; heteroplasmy; early cancer detection; next generation DNA sequencing (NGS); reactive oxygen species (ROS); surface-enhanced laser desorption ionization-based mass spectrometry (SELDI-MS);

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The anticipated biological and clinical utility of biomarkers has attracted significant interest recently. Aging and early cancer detection represent areas active in the search for predictive and prognostic biomarkers. While applications differ, overlapping biological features, analytical technologies and specific biomarker analytes bear comparison. Mitochondrial DNA (mtDNA) as a biomarker in both biological models has been evaluated. However, it remains unclear whether mtDNA changes in aging and cancer represent biological relationships that are causal, incidental, or a combination of both. This article focuses on evaluation of mtDNA-based biomarkers, emerging strategies for quantitating mtDNA admixtures, and how current understanding of mtDNA in aging and cancer evolves with introduction of new technologies. Whether for cancer or aging, lessons from mtDNA based biomarker evaluations are several. Biological systems are inherently dynamic and heterogeneous. Detection limits for mtDNA sequencing technologies differ among methods for low-level DNA sequence admixtures in healthy and diseased states. Performance metrics of analytical mtDNA technology should be validated prior to application in heterogeneous biologically-based systems. Critical in evaluating biomarker performance is the ability to distinguish measurement system variance from inherent biological variance, because it is within the latter that background healthy variability as well as high-value, disease-specific information reside.

引用

页码：165 / 179

页数：15

共 146 条

[1] A prototypical process for creating evidentiary standards for biomarkers and diagnostics [J].

Altar, C. A. ;

Amakye, D. ;

Bounos, D. ;

Bloom, J. ;

Clack, G. ;

Dean, R. ;

Devanarayan, V. ;

Fu, D. ;

Furlong, S. ;

Hinman, L. ;

Girman, C. ;

Lathia, C. ;

Lesko, L. ;

Madani, S. ;

Mayne, J. ;

Meyer, J. ;

Raunig, D. ;

Sager, P. ;

Williams, S. A. ;

Wong, P. ;

Zerba, K. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :368-371

[2] SEQUENCE AND ORGANIZATION OF THE HUMAN MITOCHONDRIAL GENOME [J].

ANDERSON, S ;

BANKIER, AT ;

BARRELL, BG ;

DEBRUIJN, MHL ;

COULSON, AR ;

DROUIN, J ;

EPERON, IC ;

NIERLICH, DP ;

ROE, BA ;

SANGER, F ;

SCHREIER, PH ;

SMITH, AJH ;

STADEN, R ;

YOUNG, IG .

NATURE, 1981, 290 (5806) :457-465

[3] Nuclear and mitochondrial DNA quantification of various forensic materials [J].

Andreasson, H. ;

Nilsson, M. ;

Budowle, B. ;

Lundberg, H. ;

Allen, M. .

FORENSIC SCIENCE INTERNATIONAL, 2006, 164 (01) :56-64

[4] Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA [J].

Andrews, RM ;

Kubacka, I ;

Chinnery, PF ;

Lightowlers, RN ;

Turnbull, DM ;

Howell, N .

NATURE GENETICS, 1999, 23 (02) :147-147

[5] Detection of mitochondrial DNA depletion in living human cells using PicoGreen staining [J].

Ashley, N ;

Harris, D ;

Poulton, J .

EXPERIMENTAL CELL RESEARCH, 2005, 303 (02) :432-446

[6] Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments [J].

Baggerly, KA ;

Morris, JS ;

Coombes, KR .

BIOINFORMATICS, 2004, 20 (05) :777-U710

[7] The yin and yang of the Cdkn2a locus in senescence and aging [J].

Baker, Darren J. ;

Jin, Fang ;

van Deursen, Jan M. .

CELL CYCLE, 2008, 7 (18) :2795-2802

[8]

BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3

[9] Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations [J].

Ballana, Ester ;

Govea, Nancy ;

De Cid, Rafael ;

Garcia, Cecilia ;

Arribas, Carles ;

Rosell, Jordi ;

Estivill, Xavier .

HUMAN MUTATION, 2008, 29 (02) :248-257

[10] What is a 'novel' mtDNA mutation - and does 'novelty' really matter? [J].

Bandelt, Hans-Juergen ;

Salas, Antonio ;

Bravi, Claudio M. .

JOURNAL OF HUMAN GENETICS, 2006, 51 (12) :1073-1082

← 1 2 3 4 5 6 7 8 9 10 →